Back to Agenda
Session 3: Applying Metrics to Patient Engagement in the BioPharma/Devices Product Lifecycle
Session Chair(s)
Roslyn Schneider, MD, FACP
Vice President, Head of Global Patient Affairs
Biomarin Pharmaceuticals Inc., United States
People and their organizations are held accountable for metrics relevant to their specific work in the development of medical products and allocation of resources is in part determined by those metrics. Patient engagement has potential benefit at discrete points and across the development lifecycle. Tools, models, and measures of quality and outcomes of those engagements are available and more are being developed. This session will outline how these may be applied to potentially improve both health and business outcomes.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe what types of patient engagement are being done at various lifecycle stages
- Apply quality guidance in planning and assessing patient engagement practices relevant to the participant’s work
- Identify measures that support strategic allocation of resources to relevant patient engagement
Speaker(s)
Applying Metrics to Patient Engagement in the BioPharma/Devices Product
Nicholas Brooke, MBA
PFMD, Belgium
Executive Director, Patient Focused Medicines Development (PFMD)
Applying Metrics to Patient Engagement in the BioPharma/Devices Product
Dawn P. Richards, PhD
Clinical Trials Ontario, Canada
Director, Patient and Public Engagement
Applying Metrics to Patient Engagement in the BioPharma/Devices Product
Roslyn Schneider, MD, FACP
Biomarin Pharmaceuticals Inc., United States
Vice President, Head of Global Patient Affairs
Have an account?